First trimester screening for congenital heart disease

Area of Science:

• Maternal-Fetal Medicine
• Diagnostic Ultrasound
• Cardiology

Background:

• Standard prenatal ultrasound at 18-20 weeks gestation includes a four-chamber view for congenital heart disease screening.
• Fetal nuchal translucency (NT) thickness, used for aneuploidy screening, also identifies fetuses with congenital heart disease.
• Congenital heart defects have been noted in chromosomally normal fetuses with increased NT in the first trimester.

Purpose of the Study:

• To review current research supporting an earlier, first-trimester approach to diagnosing congenital heart defects.
• To highlight advancements in ultrasound technology and training enabling earlier fetal cardiac assessments.
• To discuss the potential benefits of first-trimester fetal echocardiography for high-risk pregnancies.

Main Methods:

• Review of recent and ongoing clinical and basic research on early congenital heart defect diagnosis.
• Analysis of advancements in ultrasound technology and their impact on visualization rates.
• Evaluation of the efficacy of first-trimester nuchal translucency measurements in identifying cardiac anomalies.

Main Results:

• Improved ultrasound technology allows up to 90% visualization of the four-chamber view and outflow tracts by 13 weeks gestation.
• First-trimester nuchal translucency assessment can identify a significant proportion of fetuses with congenital heart disease.
• Early detection of congenital heart defects is feasible with current technology and training.

Conclusions:

• An earlier, first-trimester diagnosis of congenital heart defects is supported by recent research and technological advancements.
• First-trimester fetal echocardiography may be indicated for fetuses at increased risk of congenital heart disease.
• Implementing earlier screening protocols can potentially improve prenatal management and outcomes for congenital heart defects.